Presentation session: Multiple solid and hematological malignancies
Date:
Format: Late-breaking abstract (LBA)
Title: CS5001, a novel ROR1-targeting antibody drug conjugate (ADC) armed with tumor-cleavable ?-glucuronide linkers and pyrrolobenzodiazepine (PBD) prodrugs for hematological and solid malignancies
Speakers/Leading Principal Investigator: Dr.
CS5001 is a pre-clinical antibody-drug conjugate (ADC) completing Investigational New Drug ('IND') enabling studies. It targets ROR1 (receptor tyrosine kinase-like orphan receptor 1), a high-potential ADC target for multiple solid and hematological malignancies. ROR1 protein expression is prevalent in a variety of cancers including various forms of leukemia, non-Hodgkin lymphoma, and breast, lung and ovarian cancers, and largely absent in normal adult tissues.
CS5001 has a uniquely design tumor-cleavable linker that is conjugated to a LCB's proprietary pyrrolobenzodiazepine (PBD) prodrug. Only after reaching the tumor, the linker and prodrug are cleaved to release the PBD toxin, resulting in lethal DNA cross-links in cancer cells. The use of the linker plus PBD prodrug effectively helps addressing the toxicity problem associated with traditional PBD payloads, leading to a better safety profile. Additionally, CS5001 utilizes site-specific conjugation for a precise drug antibody ratio of 2 which enables homogeneous production and large-scale manufacturing.
In
About CStone
For more information about CStone, please visit: www.cstonepharma.com.
Forward-looking statement
The forward-looking statements made in this article only relate to events or information as of the date when the statements are made in this article. Except as required by law, we undertake no obligation to update or publicly revise any forward-looking statements, whether as a result of new information, future events or otherwise, after the date on which the statements are made or to reflect the occurrence of unanticipated events. You should read this article completely and with the understanding that our actual future results or performance may be materially different from what we expect. All statements in this article are made on the date of publication of this article and may change due to future developments.
Contact:
Tel: + 86-(0)21-6033-5000
(C) 2021 Electronic News Publishing, source